Although CRC is curable by surgery if detected in the early stages, a large proportion of patients will develop metastatic disease. For many years, 5-fluorouracil (5-FU)-based regimens (usually in combination with folinic acid [FA] [leucovorin]) have been the mainstay of chemotherapy for the treatment of advanced CRC (1). (The Advanced Colorectal Cancer Meta-Analysis Project 1992). In recent years, a number of newer agents have shown good activity in CRC. One such drug, the topoisomerase I inhibitor irinotecan, is now considered a standard choice in combination with 5-FU/FA in the first-line treatment of advanced disease (2-4) ( Table 1 ). In addition, 5-FU/FA in combination with the third-generation platinum agent, oxaliplatin, has demonstrated improved response rates and progression-free survival (PFS) compared with 5-FU/FA alone (5-7). Results from a phase III crossover study demonstrated that combinations of 5-FU/FA with irinotecan (FOLFIRI) or oxaliplatin (FOLFOX) were similarly effective in terms of response rate, PFS and tolerability, in the first-line treatment of metastatic CRC (8). There is no doubt that treatment regimens introduced in recent years have led to an increase in response rate, and survival now exceeding a median of 20 months in patients with metastatic CRC. However, there is a clear and urgent need for new treatments to improve patient outcome in both the first-and second-line settings.
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EGFR and VEGF represent potential targets for novel therapeutic intervention in CRC. The encouraging results from the phase II studies have prompted the initiation of a European two-arm study (the BOND study) (9) which is designed to compare the effects of cetuximab (n=111) with cetuximab plus irinotecan (n=218) in patients with EGFR expressing CRC which have progressed on, or within three months of, irinotecan-based chemotherapy. Patients treated with Cetuximab and Irinotecan had double as high response rate compared to patients receiving Cetuximab alone (23% vs. 11%, p=0.007) and also a significantly longer median time to progression (4.1 vs. 1.5 months, p<0.0001), while the overall survival was not statistically different albeit in favor to the combination treatment (8.6 vs. 6.9 months). A number of trials have investigated its use in combination with conventional chemotherapy for the first-line treatment of advanced CRC with promising results (10, 11) .
Inhibition of the vascular epidermal growth factor (VEGF) by the VEGF antibody bevacizimab has been reported recently. A total of 403 patients were randomized to receive the IFL regimen plus placebo and 412 IFL plus bevacizumab (12) . The response rate (35% vs. 45%, p=0.003), time to progression (6.2 vs. 10.4 months, p<0.0001) and overall survival (15.6 vs. 20.3 months, p=0.0003) were all in favor of the combination treatment. This is the first study to demonstrate VEGF inhibition as a successful target. Table 1 . Recent randomized trials with irinotecan and oxaliplatin in combination with 5-FU/FA in the first-line treatment of metastatic colorectal cancer 
